Introduction
The discovery and development of recombinant DNA technology formed the
cornerstone of the modern medical biotechnology industry. With a market valued
at almost $32 billion in 2003, the changing dynamics of the recombinant
therapeutic proteins market will have a significant impact on numerous companies
and therapy areas. This analysis seeks to identify and evaluate the key market
dynamics to 2010.
Scope of this report
- Reviews the industry's current R&D pipeline and recent business model
evolution, and deal activity of leading biotech and pharmaceutical companies
- Phase-to-phase analysis calculates the return of the sector's current
pipeline of 104 recombinant products to 2010
- Market segmentation and forecasting by leading players, key protein
classes, top-selling brands and therapeutic foci reveal key revenue trends
to 2010
Research and analysis highlights
Despite an increasing interest in protein inhibitors, fusion proteins and
tissue growth factors, innovation-driven income will not be sufficient to drive
market growth, as the sector's drug pipeline, with 28 new approvals in the next
six years, will account for just 9% of the market in 2010.
The recombinant protein market will continue to rely on blockbuster revenue
derived from 16 brands. Between 2001 and 2003 blockbuster market share increased
from 51.8% to 64.3% and is forecast to remain above 58% to 2010. Successful
lifecycle management of these 16 core brands will be critical to continued
market development.
Hematology, diabetes and endocrinology and oncology will be the most valuable
therapy areas for recombinant proteins over the forecast period. However; while
the latter two therapy areas reflect strong opportunities for future investment,
generating 44% of all pipeline products, novel products in hematology are few
and far between.
Key reasons to read this report
- Examine the portfolios of 112 companies by probing Datamonitor's
interactive recombinant therapeutic proteins analysis and forecasting tool
- Identify therapy area and class-based market opportunities and target
product development and lifecycle management strategies accordingly
- Assess current corporate strategies and evaluate partnering opportunities
for new product development, reformulation or market expansion
View Cart
